Latest Innovation News

Australian Clinical Labs reported robust FY25 financial results with revenue and earnings growth, alongside a strong dividend payout and positive outlook for FY26.

Australian Clinical Labs reported a 6.4% revenue increase and an 8.7% rise in underlying EBIT for FY25, maintaining disciplined growth and operational efficiency in a complex healthcare environment.

Fortescue Metals Group reported a robust FY25 with record iron ore shipments and strong profits, while advancing its green metal and decarbonisation initiatives. The company also provided solid FY26 guidance amid ongoing exploration and capital discipline.

Fortescue Metals Group reported a solid US$3.4 billion net profit for FY25, driven by record iron ore shipments and a strong balance sheet, while advancing ambitious decarbonisation and green energy projects.

29Metals has successfully moved its application for a new tailings storage facility at Capricorn Copper into detailed assessment, marking a critical step toward restarting operations sustainably.

29Metals Limited has reversed a significant loss to report a $35.3 million net profit for the first half of 2025, driven by stronger production at Golden Grove and improved metal prices, while Capricorn Copper remains suspended amid ongoing water and regulatory challenges.

Holista Colltech has inked a binding supply and development agreement with US-based Regenerex Pharma to exclusively supply proprietary ovine collagen for advanced wound care products, targeting the lucrative US market initially with plans for global expansion.

Noumi Limited reported modest revenue growth and a significant rise in adjusted EBITDA for FY25, driven by its Milklab brand’s strong performance and a continued turnaround in its Dairy & Nutritionals segment. The company also resolved all legacy legal issues, positioning itself for future growth.

Acusensus Limited reported a robust FY25 with 20% revenue growth and a significant 84% jump in total contract value, setting the stage for an ambitious FY26 forecast of up to 41% revenue increase.

Acusensus Limited reported a 20% increase in revenue to $59.35 million for FY25, driven by new and expanded contracts across Australia, New Zealand, the US, and the UK. However, net losses widened by 72.3%, reflecting higher operating expenses and ongoing litigation costs.

Firebrick Pharma has closed a $1.4 million placement to fund expansion of its Nasodine nasal spray in key international markets and advance new product development.

Veris Limited has reported a significant turnaround in FY25, posting a $2 million profit before tax on $97.2 million revenue, driven by growth in digital and spatial advisory services and strategic acquisitions.